Ireland
--:--IST
Latest
Clinical Trials in France / NCT05688475
Active, not recruiting Phase 1

A Rollover Study of CC-122

NCT05688475 · tracked via the Priya Life Science France tracker
Phase
Phase 1
Started
2023-04-11
Last updated
2026-05-11

Condition(s) studied

Non-Hodgkin Lymphoma

Investigational drug(s) / intervention(s)

CC-122Dexamethasone →

CC-122: Specified dose on specified days

Dexamethasone: Specified dose on specified days

Study summary

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Participant who is currently receiving CC-122 on another CC-122 clinical trial that has met its primary and secondary endpoints. * Participant who has participated in previous CC-122 protocol (including CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), and is deemed by the investigator to be deriving benefit from CC-122 as defined by the previous protocol. * Participant who is able to tolerate study therapy and has not yet experienced progressive disease or any treatment discontinuation criteria of the Parent Study. Key Exclusion Criteria: * Participant is not eligible for CC-122 treatment as per the Parent Study. * Participants not receiving clinical benefit as assessed by the investigator. Any clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the participant. * Women who are breastfeeding. Note: Other protocol-defined inclusion/exclusion criteria apply.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Local Institution - 100 New York New York
Local Institution - 101 Nashville Tennessee
Local Institution - 102 Madison Wisconsin
Local Institution - 300 Bordeaux France
Local Institution - 301 Marseille France
Local Institution - 500 Koto-ku Tokyo
Local Institution - 400 Amsterdam Netherlands

More Bristol-Myers Squibb trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05688475 on ClinicalTrials.gov ↗ ← All trials in France